Qiagen, Inovio to partner on cervical dysplasia test

2019 05 17 20 14 3434 Uterus Cervix 400

Qiagen and Inovio have announced they will develop a next-generation sequencing (NGS) test for HPV-linked advanced cervical dysplasia that can be used on Illumina's NextSeq 550Dx platform.

The liquid biopsy-based test aims to guide patient selection and offer a noninvasive alternative to having cervical lesions removed. It will be a companion test for Inovio's VGX-3100. Qiagen's expertise in bioinformatics will boost the predictive power of Inovio's preliminary biomarker signature.

Page 1 of 189
Next Page